Want to see AEON full AI Analyst Report?
Top Page
AEON Biopharma
(AEON)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.30
▲(18.40% Upside)
Action:Reiterated
Date:10/01/26
The score is primarily constrained by weak financial performance (no revenue, large losses, negative equity, and ongoing cash burn). Technicals provide only partial support (above short-term averages but still below key longer-term averages). Recent corporate updates are constructive (clearer FDA pathway, financing and regained listing compliance), but they do not fully offset the fundamental funding and profitability risks implied by the financial statements.
Positive Factors
Clearer FDA pathway
The FDA meeting feedback reduces regulatory uncertainty around ABP-450 by supporting a potentially more efficient development path. Greater clarity on study design and evidence requirements can help AEON prioritize resources and advance toward a future BLA more efficiently.
Negative Factors
Pre-revenue and loss-making
AEON has not yet generated revenue and continues to absorb substantial operating losses, leaving its financial model dependent on successful development and eventual commercialization. Until product sales or partnership income emerge, scale benefits and revenue-based operating leverage remain unavailable.
Read all positive and negative factors
Positive Factors
Negative Factors
Clearer FDA pathway
The FDA meeting feedback reduces regulatory uncertainty around ABP-450 by supporting a potentially more efficient development path. Greater clarity on study design and evidence requirements can help AEON prioritize resources and advance toward a future BLA more efficiently.
Read all positive factors
AEON Biopharma (AEON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.47M
Dividend YieldN/A
Average Volume (3M)14.20M
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS Growth35.03%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.77
Shares Outstanding49,882,790
10 Day Avg. Volume12,371,599
30 Day Avg. Volume14,199,513
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.63
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.67Price Target Upside566.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.42
Revenue Forecast (FY)N/A
AEON Biopharma Business Overview & Revenue Model
Company Description
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botuli...
How the Company Makes Money
AEON’s primary way to make money would typically be through (a) product sales following regulatory approvals and commercial launch of any therapeutic candidates, and/or (b) licensing, collaboration, and other partnership arrangements (such as upfr...
AEON Biopharma Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -25.68M | -16.22M | -27.73M | -52.74M | -52.49M | -36.88M |
| Net Income | -54.62M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
Balance Sheet | ||||||
| Total Assets | 5.91M | 5.56M | 3.14M | 6.84M | 10.78M | 6.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.43M | 3.01M | 13.00K | 5.16M | 9.75M | 5.13M |
| Total Debt | 2.77M | 35.74M | 12.96M | 278.00K | 131.53M | 86.89M |
| Total Liabilities | 21.27M | 60.59M | 31.71M | 159.89M | 281.19M | 230.26M |
| Stockholders Equity | -15.36M | -55.03M | -28.57M | -153.04M | -287.50M | -234.94M |
Cash Flow | ||||||
| Free Cash Flow | -13.64M | -17.31M | -20.29M | -47.83M | -35.89M | -28.60M |
| Operating Cash Flow | -13.64M | -17.31M | -20.29M | -47.83M | -35.58M | -28.43M |
| Investing Cash Flow | 0.00 | -4.00K | 0.00 | 0.00 | -306.00K | -170.00K |
| Financing Cash Flow | 8.63M | 20.30M | 15.15M | 14.00M | 40.51M | 13.56M |
AEON Biopharma Technical Analysis
Neutral
0.25
Price Trends
0.26
Positive
0.46
Negative
0.76
Negative
Market Momentum
>-0.01
Negative
55.10
Neutral
38.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEON, the sentiment is Neutral. The current price of 0.25 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.26, and below the 200-day MA of 0.76, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.10 is Neutral, neither overbought nor oversold. The STOCH value of 38.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AEON.
AEON Biopharma Risk Analysis
AEON Biopharma disclosed 62 risk factors in its most recent earnings report. AEON Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AEON Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $26.16M | -0.03 | -58.08% | ― | ― | 86.74% | |
47 Neutral | $14.47M | -0.07 | 204.18% | ― | ― | 35.03% | |
45 Neutral | $7.41M | -0.28 | -314.89% | ― | ― | 71.67% | |
39 Underperform | $10.57M | -1.00 | 3654.49% | ― | ― | ― |
* Healthcare Sector Average
AEON
AEON Biopharma
0.28
-0.53
-65.56%
IMNN
Imunon
1.28
-4.09
-76.16%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.16
-2.54
-54.04%
RNAZ
TransCode Therapeutics
1.57
-8.99
-85.13%
AEON Biopharma Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
AEON Biopharma advances ABP-450 biosimilar development strategy
Positive
Sep 30, 2026
On September 30, 2026, AEON Biopharma announced it had received official minutes from its Biosimilar Biological Product Development Type 2b meeting with the U.S. Food and Drug Administration, clarifying the development pathway for ABP-450 as a pro...
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
AEON Biopharma Reports Q2 Results, Advances ABP-450 Program
Positive
Aug 12, 2026
On August 12, 2026, AEON Biopharma reported second-quarter 2026 results and a corporate update, highlighting continued progress in advancing ABP-450 through the analytical phase of its biosimilar program and preparations for further FDA regulatory...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
AEON Biopharma Regains NYSE American Listing Compliance
Positive
Aug 3, 2026
On August 3, 2026, AEON Biopharma announced it had regained compliance with NYSE American’s continued listing standards related to stockholders’ equity, resolving deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE Ameri...
Business Operations and StrategyPrivate Placements and Financing
AEON Biopharma boosts liquidity with additional share sale
Positive
Jul 23, 2026
On July 15, 2026, AEON Biopharma, Inc. completed a public equity offering and, on July 23, 2026, sold an additional 4,696,102 shares of Class A common stock through a partial exercise of the underwriters’ over-allotment option, generating ap...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.